

IN THE CLAIMS

The status of each claim is provided below:

Claims 1-17: Cancelled.

18. (Currently Amended) A composition comprising an immunostimulatory oligonucleotide comprised of an octomeric CG motif of the sequence AACGTTAT in a pharmaceutically acceptable medicament with anti-tumor activity.

19. (Previously Presented) The composition of claim 18, wherein the immunostimulatory oligonucleotide is single-stranded or double-stranded.

20. (Previously Presented) The composition of claim 18, wherein the immunostimulatory oligonucleotide is stabilised.

21. (Previously Presented) The composition of claim 20, wherein the immunostimulatory oligonucleotide is stabilised by a modified backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphodiester-phosphorothioate mixture, and a stabilisation at a 3' or 5' end.

22. (Previously Presented) The composition of claim 18, wherein the immunostimulatory oligonucleotide is combined with an encapsulating agent, colloidal dispersion system, or a polymer.

23. (Previously Presented) The composition of claim 18, wherein at least one cytosine of the immunostimulatory oligonucleotide is a modified cytosine.

24. (Previously Presented) The composition of claim 23, wherein the modified cytosine is 5-bromocytosine.

25. (Previously Presented) The composition of claim 18, wherein the immunostimulatory oligonucleotide is combined with immune system cells, adjuvants of immunity, cytokines, antitumor antibodies, or tumor extracts.

26. (Previously Presented) The composition of claim 18, wherein the immunostimulatory oligonucleotide is combined with tumor cells, irradiated tumor cells, or genetically modified tumor cells.

27. (Previously Presented) The composition of claim 18, wherein the immunostimulatory oligonucleotide is between 20 and 100 nucleotides in length.

28. (Previously Presented) A composition comprised of an immunostimulatory oligonucleotide comprised of:

at least two identical octomeric CG motifs of the sequence:
AACGTTAT in a pharmaceutically acceptable medicament with antitumor activity.

29. (Previously Presented) The composition of claim 28, wherein the immunostimulatory oligonucleotide is single-stranded or double-stranded.

30. (Previously Presented) The composition of claim 28, wherein the immunostimulatory oligonucleotide is stabilised.

31. (Previously Presented) The composition of claim 28, wherein the immunostimulatory oligonucleotide is stabilized by a modified backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphodiester-phosphorothioate mixture, and a stabilization of a 3' or 5' end.

32. (Previously Presented) The composition of claim 28, wherein the immunostimulatory oligonucleotide is combined with an encapsulating agent, colloidal dispersion system, or a polymer.

33. (Previously Presented) The composition of claim 28, wherein at least one cytosine of the immunostimulatory oligonucleotide is a modified cytosine.

34. (Previously Presented) The composition of claim 33, wherein the modified cytosine is 5-bromocytosine.

35. (Previously Presented) The composition of claim 28, wherein the immunostimulatory oligonucleotide is combined with immune system cells, adjuvants of immunity, cytokines, antitumor antibodies, or tumor extracts.

36. (Previously Presented) The composition of claim 28, wherein the immunostimulatory oligonucleotide is combined with tumor cells, irradiated tumor cells, or genetically modified tumor cells.

37. (Previously Presented) An oligonucleotide comprised of:
at least three octomeric CG motifs according to a sequence
(pur-pur-C-G-pyr-pyr-X₁ X₂)
wherein the sequence (pur-pur-C-G-pyr-pyr) is palindromic and X₁X₂ is selected from the group consisting of AA, AT, CT, and TT.

38. (Currently Amended) The oligonucleotide composition of claim 37, wherein the immunostimulatory oligonucleotide is single-stranded or double-stranded.

39. (Currently Amended) The oligonucleotide composition of claim 37, wherein the immunostimulatory oligonucleotide is stabilised.

40. (Currently Amended) The oligonucleotide composition of claim 37, wherein the immunostimulatory oligonucleotide is stabilised by a modified backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphodiester-phosphorothioate mixture, and a stabilization of a 3' or 5' end.

41. (Currently Amended) The oligonucleotide composition of claim 37, wherein the immunostimulatory oligonucleotide is combined with an encapsulating agent, colloidal dispersion system, or a polymer.

42. (Currently Amended) The oligonucleotide composition of claim 37, wherein at least one cytosine of the immunostimulatory oligonucleotide is a modified cytosine.

43. (Currently Amended) The oligonucleotide composition of claim 42, wherein the modified cytosine is 5-bromocytosine.

44. (Currently Amended) The oligonucleotide composition of claim 37, wherein the immunostimulatory oligonucleotide is combined with immune system cells, adjuvants of immunity, cytokines, antitumor antibodies, or tumor extracts.

45. (Currently Amended) The oligonucleotide composition of claim 37, wherein the immunostimulatory oligonucleotide is combined with tumor cells, irradiated tumor cells, or genetically modified tumor cells.

46. (Currently Amended) The oligonucleotide composition of claim 37, wherein two of the three octomeric CG motifs are identical.

47. (Currently Amended) The oligonucleotide composition of claim 37, wherein all of the three octomeric CG motifs are identical.

48. (Currently Amended) The oligonucleotide composition of claim 37, wherein the sequence of the immunostimulatory oligonucleotide is:

TA AACGTTATAACGTTAT GACGTCAT.

49. (New) A method of treating cancer, comprising administering an effective amount of the composition of claim 18 to a human.

50. (New) The method of claim 49, wherein the cancer is a cancer of the nervous system.

51. (New) The method of claim 49, wherein the cancer is astrocytoma, glioblastoma, medulloblastoma, neuroblastoma, melanoma or carcinoma.

SUPPORT FOR THE AMENDMENTS

Claim 18 has been amended to make a grammatical change. Claims 38-48 have been amended to correct an error in the preamble. Newly-added Claims 49-51 are supported by the specification at page 8. No new matter is believed to have been added to the present application by the amendments submitted above.